Latest Breaking News On - போர்டபல் மீயொலி சிகிச்சை சாதனங்கள் - Page 1 : comparemela.com
NanoVibronix Applies for CMS Reimbursement Code for UroShield® and PainShield Plus®
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
NanoVibronix Receives Registration Approval for UroShield From TGA Australia
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
NanoVibronix Receives Registration Approval for UroShield From TGA Australia
ibtimes.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ibtimes.com.au Daily Mail and Mail on Sunday newspapers.
(NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded its reimbursement approval of the company’s PainShield™ product by adding the device to its Durable Medical Equipment (DME) schedule.
Effective immediately, PainShield is reimbursable as an approved medical device under a unique reimbursement code assigned by CMS for low frequency ultrasonic diathermy treatment specifically for home use. The product is currently the only device approved for reimbursement under the unique HCPCS code K1004, which was established through the company’s efforts and work with CMS. Visit
., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that an independent, real world patient study of its UroShield has commenced at Southampton University Health Sciences in partnership with Southern Health NHS Foundation Trust, an NHS health service provider of community services in the United Kingdom.
“This is another step forward in our efforts towards NHS fully adopting UroShield as a unique preventative device,” stated Brian Murphy, CEO of NanoVibronix. “We are eager to receive the results of this independent study as there are an estimated 100,000 patients living in community settings in the U.K. who are reliant on indwelling catheters and at risk of developing a catheter-associated urinary tract infection (CAUTI). There are also an additional 154,000 patients hospitalized annually who are catheterized for more than 48 hours and are a